Topical Propafenone Ointment for Psoriasis Immune Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, such as ultraviolet irradiation and oral or topical immunosuppressants, do not effectively address the immune system abnormalities underlying the disease, and there is a lack of information on the use of compounds of Formula I for treating or preventing psoriasis-like diseases.
Innovation Solution
The use of a compound represented by Formula I, or its pharmaceutically acceptable salts, stereoisomers, isotope derivatives, solvates, prodrugs, metal chelates, or metabolites, in the form of topical preparations, for treating and/or preventing psoriasis-like diseases, with specific structures and administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (ultraviolet irradiation, oral/topical immunosuppressants) are used for psoriasis, then treatment is provided, but they do not effectively address the immune system abnormalities underlying the disease
Solution Approach 1:
The patent introduces a novel compound with a specific chemical structure (Formula I) that represents a parameter change from conventional treatments. This compound targets immune system abnormalities directly through its molecular structure, which includes specific functional groups and substituents designed to interact with immune pathways involved in psoriasis, thereby improving reliability while offering a new treatment option.
2Reliability
If compounds of Formula I are used for treating psoriasis-like diseases, then therapeutic efficacy is achieved, but there is initially a lack of information on their use
Solution Approach 1:
The patent performs preliminary action by conducting and reporting in vivo studies using psoriasis model mice to establish the therapeutic efficacy of compounds of Formula I before clinical application. The patent document itself serves as the preliminary information source, providing detailed structural parameters, biological activity data, and dosing information that eliminates the information gap for future researchers and clinicians.
3Reliability
If topical preparations of compounds of Formula I are applied, then improved treatment outcomes are achieved, but the complexity of formulation and administration increases
Solution Approach 1:
The patent extracts the active compound of Formula I from complex systemic treatments and delivers it locally through topical preparations directly to the affected skin areas. This extraction approach concentrates the therapeutic action at the site of immune abnormalities in the skin, improving treatment outcomes while reducing systemic side effects and overall treatment complexity.
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomer, isotope derivative, solvate (such as hydrate), prodrug, metal chelate, crystal form or metabolite thereof, and a use thereof in the field of medicines. The compound, especially propafenone, can be used for treating and/or preventing psoriasis diseases. According to the present invention, it is further found that under the condition of a same administration dosage, in treating psoriasis diseases, the effect of administration by application is better than the effect of administration by injection. Compared with flecainide ointments having similar anti-arrhythmia functions, a propafenone ointment of the present invention has a better effect on treating psoriasis diseases.